Kobaltchlorid 1%

DRUG2 trials

Sponsors

Smarthealth Inc.

Conditions

Allergic contact dermatitisAllergic contact dermatitis Eczema

Phase 3

Clinical Evaluation of Metal Panel Allergens: Safety and Efficacy Study

WithdrawnCTIS2023-507972-35-00

Smarthealth Inc.Allergic contact dermatitis Eczema

Target: 105Updated: 2024-01-22

Clinical Evaluation of Metal Panel Allergens: Safety and Efficacy Study

Not yet recruitingCTIS2023-507972-35-01

Smarthealth Inc.Allergic contact dermatitis

Target: 95Updated: 2025-06-16